Sagimet Biosciences Stock
Sagimet Biosciences Inc.
Company data
- Sector
- Healthcare
- Industry
- Biotechnology
- Country
- United States
- CEO
- David Happel
- Employees
- 16
- Market cap
- $261 M
- IPO
- 14/07/2023
Sagimet Biosciences Inc. is a clinical-stage biopharmaceutical company based in the United States, operating within the Healthcare sector. The company was incorporated in 2006 and is headquartered in San Mateo. Sagimet Biosciences Inc. focuses on developing novel therapeutics known as fatty acid synthase (FASN)…
Company description based on the data provider's company data, AI-assisted, created on 15/10/2026. Not investment advice.
Sagimet Biosciences stock: price history
1D
-1.8%
1W
-10.2%
1M
-23.3%
6M
+24.0%
YTD
+35.5%
1Y
+6.2%
2Y
+46.9%
5Y
–
10Y
–
Next earnings date
Next earnings date
12/11/2026 (in 26 days)
Volatility around earnings
~21% weaker price swings than usual
Pattern chart
Pattern detected by the Market Jury detector vdouble-bottom-top-v1.0 on 15/10/26. Not a buy or sell signal.Beta
What does this mean?
Double bottom
BullishThe price bounced off a similar low twice, with a rally in between. This W-shaped pattern is a classic reversal signal from a downtrend into an uptrend.
Chart patterns are a purely technical signal derived from price action. At Market Jury they do not feed into the agents' buy or sell decisions, they are supplementary information only.
Ask the agents about Sagimet Biosciences
Analyst assessment of Sagimet Biosciences
PRICE TARGET LOW
US$7.00
CONSENSUS
US$20.00
MEDIAN
US$22.00
PRICE TARGET HIGH
US$29.00
0
STRONG BUY
8
BUY
1
HOLD
0
SELL
0
STRONG SELL
9
TOTAL · Buy
As of: 05/10/2026
Sagimet Biosciences stock metrics
P/E
-6.27
P/B
1.66
EV/EBITDA
-1.96
RETURN ON EQUITY
-5.4%
NET MARGIN
0.0%
DEBT/EQUITY
0.01
DIVIDEND YIELD
0.0%
AS OF
30/06/2026
Free float & liquidity
FREE FLOAT
95.8%
FLOAT SHARES
31,208,712
AVG. DAILY VOLUME (30D)
1,394,631
Insider transactions (SEC)
Kemble George
Kemble George
Kemble George
Kemble George
Kemble George
Institutional holders
Comparable stocks
Frequently asked questions about Sagimet Biosciences stock
What does Sagimet Biosciences do?
Sagimet Biosciences Inc. is a company in the Healthcare sector, Biotechnology industry, headquartered in United States.
The CEO is David Happel, the company employs around 16 people.
The IPO was on 14/07/2023; the stock trades on NASDAQ under the ticker SGMT.
What do analysts say about Sagimet Biosciences stock?
9 analysts rate the stock, the consensus is Buy (as of 05/10/2026).
The average price target is US$20.00, ranging from US$7.00 to US$29.00, with a median of US$22.00.
This is an external assessment, not a statement by Market Jury.
When does Sagimet Biosciences report next?
The next earnings date is 12/11/2026.
Around past earnings, price swings were roughly -21% stronger than usual.
Does Sagimet Biosciences pay a dividend?
No, Sagimet Biosciences currently does not pay a dividend.
Which stocks are comparable to Sagimet Biosciences?
Comparable stocks include Vertex Pharmaceuticals, Moderna, Regeneron Pharmaceuticals, Revolution Medicines, Incyte, Exelixis, Neurocrine Biosciences and Summit Therapeutics.
How can I get Sagimet Biosciences stock analyzed?
Clicking "Analyze stock" lets five strategies assess Sagimet Biosciences against fixed, published rules and judge it bullish, neutral or bearish. The jury states where it disagrees. A free account starts with 5 credits, a quick check costs 1 credit, a full analysis 2 credits.
Not investment advice. Past performance is not an indicator of future results.